Drug Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage

• Status: Recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Although spontaneous hyperventilation patients with aneurysmal subarachnoid hemorrhage closely associated with poor outcomes, the standard therapy remains unavailable. Remifentanil has the pharmacological characterization of respiratory inhibition, mainly prolonging the expiratory time and decreasing the respiratory rate while preserving the respiratory drive. The investigators hypothesis that spontaneous hyperventilation could be corrected by titrating the dose of remifentanil and cerebral blood flow will augment during this process.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Capital Medical University
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• Aneurysmal subarachnoid hemorrhage, after craniotomy or clipping

• Arterial blood gas satisfy with PaCO2<35mmHg and pH>7.45

• Presence of an endotracheal tube

• Assisted ventilation mode,CPAP/PSV

• ICP monitoring

Exclusion Criteria:

• Age <18 years

• Pregnancy

• Chronic obstructive pulmonary disease

• Allergy to opioids

• Clinically relevant hepatic or renal failure

• Hemodynamic instability

• TCD windows cannot detect cerebral blood flow

• Refuse to participate the study